{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:25:53Z","timestamp":1789500353222,"version":"build-2803163510"},"reference-count":119,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","mayoclinicproceedings.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.mayocp.2016.12.014","type":"journal-article","created":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T10:46:49Z","timestamp":1491216409000},"page":"663-679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":259,"title":["Neuromyelitis Spectrum Disorders"],"prefix":"10.1016","volume":"92","author":[{"given":"Brian G.","family":"Weinshenker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean M.","family":"Wingerchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.mayocp.2016.12.014_bib1","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1177\/1352458511411758","article-title":"An early case of neuromyelitis optica: on a forgotten report by Jacob Lockhart Clarke, FRS","volume":"17","author":"Jarius","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.mayocp.2016.12.014_bib2","first-page":"18","article-title":"Myelite subaigue compliquee de nevrite optique","volume":"35","author":"Devic","year":"1894","journal-title":"Bull Med"},{"issue":"5","key":"10.1016\/j.mayocp.2016.12.014_bib3","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"9451","key":"10.1016\/j.mayocp.2016.12.014_bib4","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.mayocp.2016.12.014_bib5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J\u00a0Exp Med"},{"issue":"14","key":"10.1016\/j.mayocp.2016.12.014_bib6","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1212\/WNL.0b013e318214332c","article-title":"Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications","volume":"76","author":"Popescu","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.014_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/nyas.12794","article-title":"Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later","volume":"1366","author":"Pittock","year":"2016","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"10.1016\/j.mayocp.2016.12.014_bib8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.mayocp.2016.12.014_bib9","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.mayocp.2016.12.014_bib10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","article-title":"The spectrum of MOG autoantibody-associated demyelinating diseases","volume":"9","author":"Reindl","year":"2013","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"10.1016\/j.mayocp.2016.12.014_bib11","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.014_bib12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bpa.12099","article-title":"The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica","volume":"24","author":"Lucchinetti","year":"2014","journal-title":"Brain Pathol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.014_bib13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","article-title":"Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study","volume":"75","author":"Takano","year":"2010","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.mayocp.2016.12.014_bib14","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/1352458514551455","article-title":"Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody","volume":"21","author":"Ikeda","year":"2015","journal-title":"Mult Scler"},{"issue":"7","key":"10.1016\/j.mayocp.2016.12.014_bib15","first-page":"1354","article-title":"The case of the Marquis de Causan (1804): an early account of visual loss associated with spinal cord inflammation","volume":"259","author":"Jarius","year":"2012","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.mayocp.2016.12.014_bib16","series-title":"De la neuromy\u00e9lite optique aigu\u00eb","author":"Gault","year":"1894"},{"key":"10.1016\/j.mayocp.2016.12.014_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1742-2094-10-8","article-title":"The history of neuromyelitis optica","volume":"10","author":"Jarius","year":"2013","journal-title":"J\u00a0Neuroinflammation"},{"issue":"4","key":"10.1016\/j.mayocp.2016.12.014_bib18","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/jnnp.60.4.382","article-title":"Clinical, CSF, and MRI findings in Devic's neuromyelitis optica","volume":"60","author":"O'Riordan","year":"1996","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.1016\/j.mayocp.2016.12.014_bib19","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.mayocp.2016.12.014_bib20","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.mayocp.2016.12.014_bib21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1474-4422(03)00308-9","article-title":"Multiple sclerosis in the Japanese population","volume":"2","author":"Kira","year":"2003","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.014_bib22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non-organ-specific autoimmunity","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.014_bib23","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/archneur.63.3.390","article-title":"Brain abnormalities in neuromyelitis optica","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch Neurol"},{"issue":"11","key":"10.1016\/j.mayocp.2016.12.014_bib24","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository. MRI characteristics of neuromyelitis optica spectrum disorder: an international update","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.mayocp.2016.12.014_bib25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","article-title":"A\u00a0secondary progressive clinical course is uncommon in neuromyelitis optica","volume":"68","author":"Wingerchuk","year":"2007","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.mayocp.2016.12.014_bib26","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers","volume":"67","author":"Palace","year":"2010","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.mayocp.2016.12.014_bib27","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.014_bib28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.014_bib29","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1212\/NXI.0000000000000034","article-title":"Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO","volume":"1","author":"Gelfand","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.014_bib30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jamaneurol.2014.2137","article-title":"Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders","volume":"72","author":"Flanagan","year":"2015","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/j.mayocp.2016.12.014_bib31","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1212\/01.wnl.0000183151.19351.82","article-title":"Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica","volume":"65","author":"Misu","year":"2005","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.014_bib32","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.cgh.2012.11.021","article-title":"Intractable nausea and vomiting from autoantibodies against a brain water channel","volume":"11","author":"Iorio","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.mayocp.2016.12.014_bib33","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","article-title":"Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays","volume":"78","author":"Waters","year":"2012","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.014_bib34","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1212\/NXI.0000000000000231","article-title":"Clinical utility of testing AQP4-IgG in CSF: guidance for physicians","volume":"3","author":"Majed","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.014_bib35","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/WNO.0b013e318254c62d","article-title":"Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis","volume":"32","author":"Khanna","year":"2012","journal-title":"J\u00a0Neuroophthalmol"},{"issue":"4","key":"10.1016\/j.mayocp.2016.12.014_bib36","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult Scler"},{"issue":"5","key":"10.1016\/j.mayocp.2016.12.014_bib37","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1212\/01.wnl.0000284600.80782.d5","article-title":"Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders","volume":"70","author":"Banwell","year":"2008","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.mayocp.2016.12.014_bib38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1212\/01.wnl.0000314832.24682.c6","article-title":"CNS aquaporin-4 autoimmunity in children","volume":"71","author":"McKeon","year":"2008","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.014_bib39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12974-016-0719-z","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients; Part 3: Brainstem involvement - frequency, presentation and outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J\u00a0Neuroinflammation"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.014_bib40","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients; Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J\u00a0Neuroinflammation"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.014_bib41","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients; Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J\u00a0Neuroinflammation"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.014_bib42","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients; Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients","volume":"13","author":"Pache","year":"2016","journal-title":"J\u00a0Neuroinflammation"},{"key":"10.1016\/j.mayocp.2016.12.014_bib43","first-page":"174720","article-title":"Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis","volume":"2015","author":"Etemadifar","year":"2015","journal-title":"Mult Scler Int"},{"issue":"5","key":"10.1016\/j.mayocp.2016.12.014_bib44","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann Neurol"},{"issue":"14","key":"10.1016\/j.mayocp.2016.12.014_bib45","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1177\/1352458514537699","article-title":"An epidemiological study of neuromyelitis optica in Isfahan","volume":"20","author":"Etemadifar","year":"2014","journal-title":"Mult Scler"},{"issue":"12","key":"10.1016\/j.mayocp.2016.12.014_bib46","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1177\/1352458514521503","article-title":"Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India","volume":"20","author":"Pandit","year":"2014","journal-title":"Mult Scler"},{"issue":"8","key":"10.1016\/j.mayocp.2016.12.014_bib47","first-page":"2134","article-title":"The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom","volume":"260","author":"Jacob","year":"2013","journal-title":"J\u00a0Neurol"},{"issue":"1-2","key":"10.1016\/j.mayocp.2016.12.014_bib48","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jns.2012.08.032","article-title":"Increased prevalence, incidence, and female predominance of multiple sclerosis in northern Japan","volume":"323","author":"Houzen","year":"2012","journal-title":"J\u00a0Neurol Sci"},{"issue":"4","key":"10.1016\/j.mayocp.2016.12.014_bib49","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1468-1331.2011.03529.x","article-title":"The prevalence of neuromyelitis optica in South East Wales","volume":"19","author":"Cossburn","year":"2012","journal-title":"Eur J Neurol"},{"issue":"18","key":"10.1016\/j.mayocp.2016.12.014_bib50","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1212\/WNL.0b013e3182190f74","article-title":"A\u00a0population-based study of neuromyelitis optica in Caucasians","volume":"76","author":"Asgari","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.014_bib51","first-page":"35","article-title":"An epidemiological study of neuromyelitis optica in Cuba","volume":"256","author":"Cabrera-G\u00f3mez","year":"2009","journal-title":"J\u00a0Neurol"},{"issue":"5","key":"10.1016\/j.mayocp.2016.12.014_bib52","first-page":"710","article-title":"Characteristics of Devic's disease (neuromyelitis optica) in Mexico","volume":"255","author":"Rivera","year":"2008","journal-title":"J\u00a0Neurol"},{"issue":"4","key":"10.1016\/j.mayocp.2016.12.014_bib53","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1212\/WNL.0b013e3181ea9f15","article-title":"Familial neuromyelitis optica","volume":"75","author":"Matiello","year":"2010","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.mayocp.2016.12.014_bib54","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1073\/pnas.1109980108","article-title":"Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes","volume":"109","author":"Hinson","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"pt 2","key":"10.1016\/j.mayocp.2016.12.014_bib55","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","article-title":"Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice","volume":"133","author":"Saadoun","year":"2010","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.mayocp.2016.12.014_bib56","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","article-title":"Neuromyelitis optica: pathogenicity of patient immunoglobulin in\u00a0vivo","volume":"66","author":"Bradl","year":"2009","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.mayocp.2016.12.014_bib57","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bbrc.2009.06.085","article-title":"Neuromyelitis optica: passive transfer to rats by human immunoglobulin","volume":"386","author":"Kinoshita","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.014_bib58","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bbrc.2010.02.157","article-title":"Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells","volume":"394","author":"Kinoshita","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.014_bib59","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/1352458506071174","article-title":"Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.mayocp.2016.12.014_bib60","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.mayocp.2016.12.014_bib61","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.mayocp.2016.12.014_bib62","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.mayocp.2016.12.014_bib63","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2051-5960-2-35","article-title":"Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain","volume":"2","author":"Saadoun","year":"2014","journal-title":"Acta Neuropathol Commun"},{"issue":"pt 7","key":"10.1016\/j.mayocp.2016.12.014_bib64","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A\u00a0role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.mayocp.2016.12.014_bib65","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamaneurol.2013.6331","article-title":"Paraneoplastic neuromyelitis optica spectrum disorder associated with metastatic carcinoid expressing aquaporin-4","volume":"71","author":"Figueroa","year":"2014","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/j.mayocp.2016.12.014_bib66","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/00207454.2013.854208","article-title":"Is neuromyelitis optica with advanced age of onset a paraneoplastic disorder?","volume":"124","author":"Ontaneda","year":"2014","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.mayocp.2016.12.014_bib67","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1471-2415-14-106","article-title":"Paraneoplastic neuromyelitis optica associated with ANNA-1 antibodies in invasive thymoma","volume":"14","author":"Yang","year":"2014","journal-title":"BMC Ophthalmol"},{"issue":"4","key":"10.1016\/j.mayocp.2016.12.014_bib68","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5414\/NP300855","article-title":"Anti-aquaporin 4 related paraneoplastic neuromyelitis optica in the presence of adenocarcinoma of the lung","volume":"34","author":"Verschuur","year":"2015","journal-title":"Clin Neuropathol"},{"issue":"5","key":"10.1016\/j.mayocp.2016.12.014_bib69","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/glia.22635","article-title":"Neuromyelitis optica IgG stimulates an immunological response in rat astrocyte cultures","volume":"62","author":"Howe","year":"2014","journal-title":"Glia"},{"key":"10.1016\/j.mayocp.2016.12.014_bib70","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12974-015-0403-8","article-title":"NF\u03baB signaling drives pro-granulocytic astroglial responses to neuromyelitis optica patient IgG","volume":"12","author":"Walker-Caulfield","year":"2015","journal-title":"J\u00a0Neuroinflammation"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.014_bib71","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/1352458509350741","article-title":"HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis","volume":"16","author":"Brum","year":"2010","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.mayocp.2016.12.014_bib72","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1007\/s12264-013-1457-1","article-title":"No association between identified multiple sclerosis non-MHC risk loci and neuromyelitis optica","volume":"30","author":"Liu","year":"2014","journal-title":"Neurosci Bull"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.014_bib73","doi-asserted-by":"crossref","first-page":"e58925","DOI":"10.1371\/journal.pone.0058925","article-title":"European ancestry predominates in neuromyelitis optica and multiple sclerosis patients from Brazil","volume":"8","author":"Brum","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.mayocp.2016.12.014_bib74","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1212\/WNL.0b013e31822f045b","article-title":"Genetic analysis of aquaporin-4 in neuromyelitis optica","volume":"77","author":"Matiello","year":"2011","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.mayocp.2016.12.014_bib75","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jneuroim.2014.07.003","article-title":"Human aquaporin 4 gene polymorphisms in Chinese patients with neuromyelitis optica","volume":"274","author":"Wei","year":"2014","journal-title":"J\u00a0Neuroimmunol"},{"issue":"20","key":"10.1016\/j.mayocp.2016.12.014_bib76","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1212\/WNL.0b013e31825644ff","article-title":"Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients","volume":"78","author":"Leite","year":"2012","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.mayocp.2016.12.014_bib77","first-page":"3185","article-title":"Aquaporin-4 antibody neuromyelitis optica following anti-NMDA receptor encephalitis","volume":"260","author":"Zoccarato","year":"2013","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.mayocp.2016.12.014_bib78","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jocn.2015.08.006","article-title":"Brainstem and limbic encephalitis with paraneoplastic neuromyelitis optica","volume":"23","author":"Moussawi","year":"2016","journal-title":"J\u00a0Clin Neurosci"},{"issue":"4","key":"10.1016\/j.mayocp.2016.12.014_bib79","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/WNL.0000000000001792","article-title":"Neuromyelitis optica in a child with Aicardi-Gouti\u00c8res syndrome","volume":"85","author":"Hacohen","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.014_bib80","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/jnnp-2012-302925","article-title":"Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status","volume":"84","author":"Yoshimura","year":"2013","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.014_bib81","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ana.23651","article-title":"Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter","volume":"72","author":"Varrin-Doyer","year":"2012","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.014_bib82","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ana.24718","article-title":"Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens","volume":"80","author":"Cree","year":"2016","journal-title":"Ann Neurol"},{"issue":"9","key":"10.1016\/j.mayocp.2016.12.014_bib83","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/archneurol.2012.1300","article-title":"Human aquaporin 4281-300 is the immunodominant linear determinant in the context of HLA-DRB1*03:01: relevance for diagnosing and monitoring patients with neuromyelitis optica","volume":"69","author":"Arellano","year":"2012","journal-title":"Arch Neurol"},{"issue":"9","key":"10.1016\/j.mayocp.2016.12.014_bib84","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"10.1016\/j.mayocp.2016.12.014_bib85","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.014_bib86","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1212\/NXI.0000000000000104","article-title":"B\u00a0lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"17","key":"10.1016\/j.mayocp.2016.12.014_bib87","doi-asserted-by":"crossref","first-page":"13829","DOI":"10.1074\/jbc.M112.344325","article-title":"Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays","volume":"287","author":"Phuan","year":"2012","journal-title":"J\u00a0Biol Chem"},{"issue":"9","key":"10.1016\/j.mayocp.2016.12.014_bib88","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1001\/jamaneurol.2013.3124","article-title":"Aquaporin 4 expression and tissue susceptibility to neuromyelitis optica","volume":"70","author":"Matiello","year":"2013","journal-title":"JAMA Neurol"},{"issue":"13","key":"10.1016\/j.mayocp.2016.12.014_bib89","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1177\/1352458515571446","article-title":"Role of membrane complement regulators in neuromyelitis optica","volume":"21","author":"Saadoun","year":"2015","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.014_bib90","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ana.22686","article-title":"Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain","volume":"71","author":"Saadoun","year":"2012","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.mayocp.2016.12.014_bib91","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1172\/JCI67554","article-title":"Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica","volume":"123","author":"Zhang","year":"2013","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.mayocp.2016.12.014_bib92","doi-asserted-by":"crossref","first-page":"e33878","DOI":"10.1371\/journal.pone.0033878","article-title":"White matter atrophy and cognitive dysfunctions in neuromyelitis optica","volume":"7","author":"Blanc","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.mayocp.2016.12.014_bib93","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A\u00a0randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.mayocp.2016.12.014_bib94","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.mayocp.2016.12.014_bib95","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks\u00a0and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.014_bib96","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11940-008-0007-z","article-title":"Neuromyelitis optica","volume":"10","author":"Wingerchuk","year":"2008","journal-title":"Curr Treat Options Neurol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.014_bib97","first-page":"575","article-title":"Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study","volume":"263","author":"Ayzenberg","year":"2016","journal-title":"J\u00a0Neurol"},{"issue":"4","key":"10.1016\/j.mayocp.2016.12.014_bib98","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of neuromyelitis optica: review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.mayocp.2016.12.014_bib99","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","article-title":"Devic's neuromyelitis optica: a prospective study of seven patients treated with\u00a0prednisone and azathioprine","volume":"51","author":"Mandler","year":"1998","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.mayocp.2016.12.014_bib100","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.mayocp.2016.12.014_bib101","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458514525870","article-title":"Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult Scler"},{"issue":"9","key":"10.1016\/j.mayocp.2016.12.014_bib102","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of\u00a0neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch Neurol"},{"issue":"11","key":"10.1016\/j.mayocp.2016.12.014_bib103","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","article-title":"Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder","volume":"71","author":"Huh","year":"2014","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/j.mayocp.2016.12.014_bib104","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A\u00a05-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.014_bib105","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1352458515587752","article-title":"Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints","volume":"22","author":"Jeong","year":"2016","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.014_bib106","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol"},{"issue":"10","key":"10.1016\/j.mayocp.2016.12.014_bib107","first-page":"2329","article-title":"Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability","volume":"262","author":"Z\u00e9phir","year":"2015","journal-title":"J\u00a0Neurol"},{"issue":"8","key":"10.1016\/j.mayocp.2016.12.014_bib108","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/1352458507077189","article-title":"Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult Scler"},{"issue":"8","key":"10.1016\/j.mayocp.2016.12.014_bib109","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/jnnp-2012-304774","article-title":"Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies","volume":"84","author":"Kitley","year":"2013","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.mayocp.2016.12.014_bib110","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archneurol.2010.322","article-title":"Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"issue":"9","key":"10.1016\/j.mayocp.2016.12.014_bib111","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","article-title":"Treatment of neuromyelitis optica: state-of-the-art and emerging therapies","volume":"10","author":"Papadopoulos","year":"2014","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.014_bib112","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s13311-015-0400-8","article-title":"Present and future therapies in neuromyelitis optica spectrum disorders","volume":"12","author":"Kleiter","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.014_bib113","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","article-title":"Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy","volume":"70","author":"Ayzenberg","year":"2013","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.014_bib114","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamaneurol.2013.668","article-title":"Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses","volume":"70","author":"Kieseier","year":"2013","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/j.mayocp.2016.12.014_bib115","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.014_bib116","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","article-title":"Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica","volume":"71","author":"Tradtrantip","year":"2012","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.mayocp.2016.12.014_bib117","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1096\/fj.11-201608","article-title":"Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica","volume":"26","author":"Tradtrantip","year":"2012","journal-title":"FASEB J"},{"issue":"6","key":"10.1016\/j.mayocp.2016.12.014_bib118","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.014_bib119","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1212\/NXI.0000000000000062","article-title":"Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?","volume":"2","author":"Zamvil","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619616308497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619616308497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T01:50:27Z","timestamp":1535939427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619616308497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":119,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0025619616308497"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2016.12.014","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuromyelitis Spectrum Disorders","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2016.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}